echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > BMC Gastroenterology: The levels of IL-17 and alpha-fetoprotein in plasma can effectively predict the risk of liver cancer in patients with liver cirrhosis

    BMC Gastroenterology: The levels of IL-17 and alpha-fetoprotein in plasma can effectively predict the risk of liver cancer in patients with liver cirrhosis

    • Last Update: 2021-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cirrhosis of the liver is a life-threatening disease, which causes more than 1 million deaths worldwide every year.


    Cirrhosis of the liver is a life-threatening disease, which causes more than 1 million deaths worldwide every year.


     

     

    The latest research revealed that the pro-inflammatory cytokine interleukin 17 (IL-17) is related to the pathogenesis of liver fibrosis, cirrhosis and autoimmune hepatitis.


     

     

    The researchers recruited 404 patients with liver cirrhosis without HCC into this study and were followed up regularly.


    Figure: The predictive ability of different combinations of IL-17 and biomarkers for liver cancer

     

    This study confirmed that the concentration of IL-17 in the serum of patients with liver cirrhosis is an effective predictor of subsequent HCC in patients with liver cirrhosis.


    This study confirmed that the concentration of IL-17 in the serum of patients with liver cirrhosis is an effective predictor of subsequent HCC in patients with liver cirrhosis.


     

    Original source:

    Kung-Hao Liang.


    biomedcentral.
    com/articles/10.
    1186/s12876-021-01761-1" target="_blank" rel="noopener">Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.